Topical therapy with clobetasol propionate 0.025% for various dermatological conditions

Authors

  • Vishwanath Prem Raj Department of Dermatology, Deepak Skin and Laser Cosmotic Clinic, Andhra Pradesh
  • Nitin Pandit Tayade Department of Dermatology, Palneet Clinic, Mumbai
  • Chandrashekhar V. Kiswe Department of Dermatology, Kiswe Clinic, Nanded, Mumbai
  • Nimesh Surendrakumar Shah Department of Dermatology, Sparsh Skin Care & Cosmetology Centre, Gujarat
  • Suneel Singh Sengar Department of Dermatology, Sengar Sampurna Skin Clinic, Indore
  • Indira Pavan Department of Dermatology, Omega Clinics, Hyderabad
  • Sanjay Ramanbhai Gamit Department of Dermatology, Silvassa Ho, Gujarat
  • Mohit Bansal Department of Dermatology, Dr Mohit Bansal Skin Care & Cosmetic Laser Center, Rajasthan
  • Sachin Kumar Department of Dermatology, Karuna Hospital, Delhi
  • Ankit Yadav Department of Dermatology, Netaji Subhash Chandra Bose Medical College, Jabalpur,Madhya Pradesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20220301

Keywords:

Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Abstract

Topical corticosteroids (TC) are the most commonly prescribed medications for the treatment of several dermatoses. Owing to their potent effect of relieving symptoms, these drugs are indicated for the use of inflammatory and pruritic presentations of dermatologic conditions. Clobetasol propionate (CP) is the most common TC used to treat itching, redness, and swelling caused by some skin conditions. It possesses anti-inflammatory, antipruritic, and vasoconstrictive properties. To exert its effect, CP binds to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor-mediated gene expression, thus resulting in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. This case series discusses the efficacy, safety, and clinical experience of using CP 0.025% cream for the treatment of different dermatologic conditions.

References

Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532940/. Accessed on 18 November 2021.

Rathi SK, D’Souza1 P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251-59.

Pels R, Sterry W, Lademann J. Clobetasol propionate--where, when, why? Drugs Today (Barc). 2008;44(7):547-57.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Meglio PDVillanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354.

Sidgiddi S, Naqvi SMH, Shenoy M. Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: Phase-2a, randomized 3-arm study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.

Downloads

Published

2022-01-29

How to Cite

Raj, V. P., Tayade, N. P., Kiswe, C. V., Shah, N. S., Sengar, S. S., Pavan, I., Gamit, S. R., Bansal, M., Kumar, S., & Yadav, A. (2022). Topical therapy with clobetasol propionate 0.025% for various dermatological conditions. International Journal of Research in Medical Sciences, 10(2), 512–518. https://doi.org/10.18203/2320-6012.ijrms20220301

Issue

Section

Case Series